TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17126588

Group type: EXPERIMENTAL
Intervention: Rigid gas permeable lenses of varying thicknesses (0.18, 0.12, 0.16, 0.20, 0.24, 0.28, and 0.32 mm)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) contact lens
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal open eye
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Static wear of lenses
Number of subjects: 14
Study: 15857205

Group type: EXPERIMENTAL
Intervention: Spirulina (2,000 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spirulina (1,000 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11972740

Group type: COMPARATOR
Intervention: Formula with 0.4% ALA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Formula with 1.0% ALA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Formula with 1.7% ALA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Formula with 3.2% ALA
Number of subjects: 44
Study: 10466547

Group type: EXPERIMENTAL
Intervention: DTPw-HBV combination vaccine containing 10 microg of HBsAg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTPw-HBV combination vaccine containing 5 microg of HBsAg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate administration of DTPw and HBV (10 microg of HBsAg)
Number of subjects: 0
Study: 7838634

Group type: EXPERIMENTAL
Intervention: Rice flour-ORS (RF-ORS)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Glucose-ORS (G-ORS)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Rice dextrin-ORS (RD-ORS)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: All groups (RF-ORS, G-ORS, RD-ORS)
Number of subjects: 146
Study: 2244843

Group type: EXPERIMENTAL
Intervention: Ticlopidine (antiplatelet agent)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 386494

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 31960259

Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) intervention
Number of subjects: 3084

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3084
Study: 30836195

Group type: EXPERIMENTAL
Intervention: PEMF therapy (immediate post-surgery for 6 hours, then 3 hours for the next 6 days, and 1.5 hours for days 8-13)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional therapy (no extra treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PEMF therapy
Number of subjects: 32
Study: 28953308

Group type: EXPERIMENTAL
Intervention: ET-View
Number of subjects: 50

Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 50
Study: 25829374

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) using a patient decision aid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient decision aid
Number of subjects: 0
Study: 25128922

Group type: EXPERIMENTAL
Intervention: Alveolar corticotomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (conventional technique)
Number of subjects: 30
Study: 22521233

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (flexible dose of one of five antipsychotic medications)
Number of subjects: 0
Study: 19081265

Group type: EXPERIMENTAL
Intervention: HeLM intervention group (n=29)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation group (n=22)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 17907491

Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 45
Study: 15196297

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 12202464

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 0
Study: 10102948

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 2 weeks
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 4 weeks
Number of subjects: 205

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 2 weeks
Number of subjects: 205

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 4 weeks
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 205
Study: 7480102

Group type: EXPERIMENTAL
Intervention: Sugar-coated tablet formulation containing 50 mg standardized horse chestnut seed extract
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference preparation in capsule form containing 50 mg standardized horse chestnut seed extract
Number of subjects: 18
Study: 1702449

Group type: EXPERIMENTAL
Intervention: RU 486 (mifepristone)
Number of subjects: 0
Study: 7389382

Group type: EXPERIMENTAL
Intervention: 500 mg pivampicillin twice daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin 3-times daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: 100 mg doxycycline daily
Number of subjects: 106
Study: 31350847

Group type: EXPERIMENTAL
Intervention: HiFreSP (high-frequency sub-pathways mining approach)
Number of subjects: 8137

Group type: EXPERIMENTAL
Intervention: HiFreSP
Number of subjects: 8137
Study: 31315871

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Funding from industry
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Overall Quality Score (OQS)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Quality items (objective, conclusions, funding)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Authors, randomisation, outcome reporting
Number of subjects: 176
Study: 27324087

Group type: EXPERIMENTAL
Intervention: Report cards with numerical design
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Report cards with textual information
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Report cards with star ratings
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Report cards without narrative comments
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Report cards with narrative comments
Number of subjects: 1350
Study: 26002889

Group type: EXPERIMENTAL
Intervention: Oxygen (8 L/min)
Number of subjects: 441

Group type: COMPARATOR
Intervention: No supplemental oxygen
Number of subjects: 441
Study: 24169081

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg once daily
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg on demand
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 22708612

Group type: EXPERIMENTAL
Intervention: Experimental treatment (observation and immediate imitation of common daily hand and arm actions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual rehabilitation without any trial-related treatment
Number of subjects: 0
Study: 19630125

Group type: EXPERIMENTAL
Intervention: One leg cycling aerobic training program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (without cardiorespiratory training)
Number of subjects: 24
Study: 17560448

Group type: EXPERIMENTAL
Intervention: Sputum-submission guidance
Number of subjects: 1494

Group type: COMPARATOR
Intervention: No specific guidance (control)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Instructions for men
Number of subjects: 1494
Study: 15366525

Group type: EXPERIMENTAL
Intervention: Chin cup therapy
Number of subjects: 0
Study: 11254519

Group type: EXPERIMENTAL
Intervention: APAP(FOT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 52
Study: 11564007

Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg b.d.
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 881

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Tegaserod (both dosages)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 881
Study: 9216951

Group type: EXPERIMENTAL
Intervention: High-low group (living at moderate altitude 2,500 m and training at low altitude 1,250 m)
Number of subjects: 39

Group type: COMPARATOR
Intervention: High-high group (living and training at moderate altitude 2,500 m)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-low group (living and training in a mountain environment at sea level 150 m)
Number of subjects: 39
Study: 8122739

Group type: EXPERIMENTAL
Intervention: Preoxygenation for three minutes with 100% oxygen ventilation
Number of subjects: 80

Group type: COMPARATOR
Intervention: No preoxygenation with 100% oxygen ventilation
Number of subjects: 80

Group type: COMPARATOR
Intervention: No preoxygenation with 50% oxygen ventilation
Number of subjects: 80

Group type: COMPARATOR
Intervention: No preoxygenation with 33% oxygen ventilation
Number of subjects: 80
Study: 3310569

Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 160 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Acebutolol (400 mg/day)
Number of subjects: 15
Study: 1704983

Group type: EXPERIMENTAL
Intervention: Felodipine plus metoprolol 10 + 100 mg (FM)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Felodipine 10 mg (F)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Metoprolol 100 mg (M)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Felodipine plus metoprolol (FM)
Number of subjects: 159
Study: 168121

Group type: EXPERIMENTAL
Intervention: Intravenous adrenocorticotropic hormone (ACTH)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intravenous hydrocortisone
Number of subjects: 22
Study: 31618446

Group type: EXPERIMENTAL
Intervention: Sertraline and/or mirtazapine
Number of subjects: 2011
Study: 27600280

Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin-bevacizumab (PCB) with nitroglycerin patches
Number of subjects: 223

Group type: COMPARATOR
Intervention: Paclitaxel-carboplatin-bevacizumab (PCB) without nitroglycerin patches (control)
Number of subjects: 223
Study: 26376600

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 801

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 801
Study: 24419513

Group type: EXPERIMENTAL
Intervention: Once-daily (QD) administration of intra-venous (IV) BU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four-times-daily (4QD) administration of intra-venous (IV) BU
Number of subjects: 0
Study: 21905890

Group type: EXPERIMENTAL
Intervention: Screw-retained prostheses (SP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cemented prostheses (CP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cemented prostheses (CP) and Screw-retained prostheses (SP)
Number of subjects: 40
Study: 19237406

Group type: EXPERIMENTAL
Intervention: Standardised consultation
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study: 17880350

Group type: EXPERIMENTAL
Intervention: Reduced appraisals of past harm from baseline to end of treatment
Number of subjects: 252

Group type: COMPARATOR
Intervention: Increased harm appraisals from baseline to end of treatment
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Higher treatment intensity and 12-step affiliation
Number of subjects: 252
Study: 15144668

Group type: EXPERIMENTAL
Intervention: Composite graft of acellular allo-dermis matrix (ADM) with thin auto-microskin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Auto-microskin grafted
Number of subjects: 8
Study: 11834118

Group type: EXPERIMENTAL
Intervention: Modified Closed Kinetic Chain (MCKC) knee extension exercises
Number of subjects: 8

Group type: COMPARATOR
Intervention: Traditional Open Kinetic Chain (OKC) knee extension exercises
Number of subjects: 8
Study: 9806528

Group type: EXPERIMENTAL
Intervention: Prostate radiotherapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bladder and rectal volumes
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Margins between the CTV and PTV
Number of subjects: 17
Study: 8548939

Group type: EXPERIMENTAL
Intervention: Methimazole treatment in TBII negative patients (Group A)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Methimazole treatment in TBII positive patients (Group B)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (Group C) - TBII positive patients
Number of subjects: 94

Group type: COMPARATOR
Intervention: Comparison of TBII levels
Number of subjects: 94

Group type: COMPARATOR
Intervention: Comparison of TSAb levels
Number of subjects: 94

Group type: COMPARATOR
Intervention: Thyroid volumes
Number of subjects: 94
Study: 2173354

Group type: EXPERIMENTAL
Intervention: Long-term diazepam treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acute i.v. diazepam administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study: 687499

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrallazine plus propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period (cold pressor test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol during cold pressor test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrallazine
Number of subjects: 0
Study: 29963733

Group type: EXPERIMENTAL
Intervention: Interval aerobic training programme with active recovery bouts (IATP-R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control)
Number of subjects: 60
Study: 27882605

Group type: EXPERIMENTAL
Intervention: 6 mg/kgBM caffeine (CAF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42
Study: 25830782

Group type: EXPERIMENTAL
Intervention: Walk@WorkSpain (W@WS) intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Comparison group (maintained normal behavior)
Number of subjects: 264
Study: 23998234

Group type: EXPERIMENTAL
Intervention: 400 mg of docosahexaenoic acid
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 21430660

Group type: EXPERIMENTAL
Intervention: Tocilizumab infusion
Number of subjects: 12
Study: 19739914

Group type: EXPERIMENTAL
Intervention: Self-help memory training program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-based memory training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 18180893

Group type: EXPERIMENTAL
Intervention: Qingre Liyan Decoction (QRLYD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dobell's solution (Control)
Number of subjects: 60
Study: 14745658

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg) and Fluticasone (250 microg) in a single dry powder inhaler (Diskus)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Fluticasone propionate (500 microg) twice daily
Number of subjects: 365
Study: 11207464

Group type: EXPERIMENTAL
Intervention: Lidocaine 50 mg with adrenaline
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg with adrenaline
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline/adrenaline
Number of subjects: 22
Study: 9435413

Group type: EXPERIMENTAL
Intervention: Active buccal tablet containing 10 mg testosterone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Buccal placebo tablet containing 3 mg pseudoephedrine HCl for taste matching
Number of subjects: 13
Study: 8608205

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation for one night
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 7-day treatment with chlormadinone acetate (CMA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 7-day treatment with acetazolamide (ACET)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 121
Study: 2583007

Group type: EXPERIMENTAL
Intervention: Intervention group (8 educational lessons)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Control group (no activities)
Number of subjects: 752
Study: 1102231

Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Morphine 12 mg
Number of subjects: 74
Study: 31468673

Group type: EXPERIMENTAL
Intervention: Biyeom-go treatment >3 times daily for a total of 4 weeks
Number of subjects: 58
Study: 29908675

Group type: EXPERIMENTAL
Intervention: Cocoa powder (30 g) and dark chocolate (50 g) daily for 1 week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27166583

Group type: COMPARATOR
Intervention: Nutrition only
Number of subjects: 290

Group type: COMPARATOR
Intervention: Nutrition + CBT
Number of subjects: 290

Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control
Number of subjects: 290
Study: 24351886

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Thiamylal
Number of subjects: 87
Study: 22120130

Group type: EXPERIMENTAL
Intervention: omega-3 group (6 g/d fish oil; n = 91)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (n = 87)
Number of subjects: 178
Study: 20621377

Group type: COMPARATOR
Intervention: One-year intervention group (OIG, n=23)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Two-year intervention group (TIG, n=25)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (CG, n=75)
Number of subjects: 123
Study: 18416220

Group type: EXPERIMENTAL
Intervention: Zero-balanced ultrafiltration (ZBUF) (50 ml/kg) and conventional ultrafiltration (CUF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF) only
Number of subjects: 20
Study: 15050249

Group type: EXPERIMENTAL
Intervention: ThinOptX IOL
Number of subjects: 28

Group type: COMPARATOR
Intervention: AcrySof IOL
Number of subjects: 28
Study: 11856139

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 230

Group type: COMPARATOR
Intervention: Open antireflux surgery
Number of subjects: 230
Study: 9639442

Group type: EXPERIMENTAL
Intervention: Surgically excised CNV specimens from patients with ARMD
Number of subjects: 160

Group type: COMPARATOR
Intervention: Surgically excised CNV specimens from non-ARMD patients
Number of subjects: 160
Study: 8073431

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50-150 mg for five consecutive days in each treatment cycle
Number of subjects: 608
Study: 2800898

Group type: EXPERIMENTAL
Intervention: 10% cyclosporin gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study: 1090222

Group type: EXPERIMENTAL
Intervention: Paraldehyde (10 ml rectally every 30 minutes)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg then 5 mg intravenously every 5 minutes)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diazepam (intramuscularly)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Paraldehyde (rectally)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Paraldehyde
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 34
Study: 31094261

Group type: EXPERIMENTAL
Intervention: Optimum Power Load (OPL) training (squat + hip thrust exercises at maximum power output)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of OPL vs PT
Number of subjects: 0
Study: 30719774

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma coverage layer
Number of subjects: 180

Group type: COMPARATOR
Intervention: Dartos flap
Number of subjects: 180
Study: 28710339

Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: CT screening with additional clinical investigation
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: CT screening with negative result
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Usual care (no screening)
Number of subjects: 1546
Study: 26292720

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta‐VNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular non‐vagus nerve stimulation (tan‐VNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 0
Study: 24018915

Group type: EXPERIMENTAL
Intervention: Multimedia-based surgical procedure manual (MMG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Text-based surgical procedure manual (TG)
Number of subjects: 101
Study: 21157359

Group type: EXPERIMENTAL
Intervention: Thermal suit (T‐Balance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional clothing (control)
Number of subjects: 40
Study: 18349403

Group type: EXPERIMENTAL
Intervention: Observation without cytotoxic treatment
Number of subjects: 340

Group type: COMPARATOR
Intervention: Surgery or chemotherapy
Number of subjects: 340
Study: 16574044

Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 12249
Study: 14674492

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 9
Study: 10762214

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 8609945

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (7.5 to 17.5 mg per week), sulfasalazine (500 mg twice daily), and hydroxychloroquine (200 mg twice daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Methotrexate alone (7.5 to 17.5 mg per week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Combination of sulfasalazine (500 mg twice daily) and hydroxychloroquine (200 mg twice daily)
Number of subjects: 102
Study: 8272478

Group type: EXPERIMENTAL
Intervention: Nondirected use of pictures (art stimulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no art stimulation)
Number of subjects: 40